Siewert type II esophagogastric junction adenocarcinoma
Conditions
Interventions
Test group:Tirelizumab combined with oxaliplatin and tigio neoadjuvant therapy
Sponsors
The Fourth Hospital of Hebei Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Aged between 18 and 75; (2) It was pathologically confirmed as esophagogastric junction adenocarcinoma with Siewert type II (3) Clinical tumor stage: T2-4N0-3M0; (4) There is at least one measurable lesion; (5) ECOG PS score: 0-1; (6) Major organ function is normal, and baseline tests such as blood tests have no contraindications for immunotherapy and chemotherapy.
Exclusion criteria
Exclusion criteria: (1) Use of immunosuppressive drugs in the 14 days prior to administration, excluding inhaled corticosteroids or physiological doses of systemic steroids; (2) Existing active autoimmune disease or history of autoimmune disease before administration; (3) Combined with other malignant tumors; (4) Patients with active viral hepatitis B (HBV DNA = 100 IU/ml), viral hepatitis C, and need antiviral therapy during treatment; (5) Have a history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation; (6) Persons with mental disorders; (7) HER2-positive patients; (8) Clinical assessment is not suitable for patients participating in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pathologic Complete Response; | — |
Secondary
| Measure | Time frame |
|---|---|
| MajorPathological Response;Complete tumor resection rate;Objective Response Rate;Disease-Free Survival; | — |
Countries
China
Contacts
Public ContactTian Ziqaing
The Fourth Hospital of Hebei Medical University
Outcome results
None listed